Insulin-Loaded Prosochit® Nanoparticles Formulation Inhibits Lymphocytosis in Alloxan-Induced Diabetic Rats
Article Sidebar
Main Article Content
Abstract
Haematological disorder is one of the manifestations in diabetes mellitus. This study aimed to investigate the effect of oral insulin-loaded Prosochit® nanoparticles on blood composition in diabetes. Twenty rats were selected from a community of alloxan-induced diabetic rats, divided into four equal groups and labelled Groups 1 to 4. Another group of 5 rats was kept without induction and without treatment as the healthy control group and labelled HCG. Group 1 animals were administered purified water (untreated), Group 2 was treated with oral insulin-loaded Prosochit® nanoparticles, Group 3 with oral unloaded Prosochit® nanoparticles and Group 4 with subcutaneous insulin - Actrapid® (positive control). The drug administration at the dose of 50 IU/kg was done daily for 28 days. Blood samples were taken and analyzed for glucose level on Days 0, 1 and 28. The samples were also subjected to complete blood count. After 24 h of commencing treatment, insulin-loaded Prosochit® nanoparticles limited the increase in the lymphocytes count to 4.08 x 109/L compared to the untreated group with the count of 6.23 x 109/L. It also brought forth a slight reduction in haemoglobin level to 11.5 g/L and maintained the number of platelets closest to the normal range. After 28 days, the lymphocytes count only increased to 4.56×109 /L while that of the untreated diabetic group had increased to 8.92×109 /L. The red blood cells and platelets counts were similar to those of the healthy rats. Oral insulin-loaded Prosochit® nanoparticles inhibits lymphocytosis in alloxan-induced diabetic rats.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
Makhlof A, Tozuka Y, Takeuchi H. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci. 2011; 42:445-451. doi: 10.1016/j.ejps.2010.12.007.
Mumuni MA, Ernest OC, Ebele O, Kenechukwu FC, Salome CA, Chinekwu NS, Aminu N, Ben A. Development and characterization of mucinated chitosan microcomposite for oral insulin delivery. Trop J Nat Prod Res. 2020; 4:1000-1006. https://doi.org/10.26538/tjnpr/v4i11.27.
White S, Bennet DB, Cheu S, Gray S, Seshadri N, Parker JM, Sluggett GW, Malcomson R, Conley PW. Exubera: Pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther. 2005; 7:896–906. doi: 10.1089/dia.2005.7.896.
Olorunsola EO, Alozie MF, Davies KG, Adedokun MO. Advances in the science and technology of insulin delivery: a review. J Appl Pharm Sci. 2021; 11(08):184–191. doi: 10.7324/JAPS.2021.110824
Khafagy ES, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: A comparative review. Adv Drug Deliv Rev. 2007; 59:1521–1546. doi: 10.1016/j.addr.2007.08.019.
Verma A, Kumar N, Malviya R, Sharma PK. Emerging trends in noninvasive insulin delivery. J Pharmaceut. 2014; Article 378048:1-9. https://doi.org/10.1155/2014/378048.
Olorunsola EO, Udoh IE, Ekott MB, Alozie MF and Davies KG. Biopharmaceutics and clinical outcomes of emerging dosage forms of insulin: A systematic review. Diabetes Epidemiol Manag. 2023; 9: Article 100120. https://doi.org/10.1016/j.deman.2022.100120.
Shah RB, Patel M, Maahs DM, Shah VN. Insulin delivery methods: Past, present and future. Int J Pharm Investig. 2016; 6(1):1-9. doi: 10.4103/2230-973X.176456.
Krisna AP, Ningrum HW, Fimannuha TL, Puspita OE. Systematic review on the effectiveness of strategies for increasing insulin bioavailability in oral route delivery system based on manufacturing techniques and materials used. J Drug Deliv Ther. 2021; 11(6). doi: 10.22270/jddt.v11i6.5132.
Olorunsola EO, Davies KG, Essien EB, Alozie MF, Adedokun MO, Ahsan F. Orally administered Prosochit-based nanoparticles of insulin ameliorates alloxan-induced diabetes in rats. Sci Pharm. 2022; 90(4):66. doi: 10.3390/scipharm90040066.
Olorunsola EO, Adedokun MO, Bhatia PG, Tytler BA, Adikwu MU. Optimization of artesunate delivery by formulation in a delayed release prosopis hemicellulose matrix. J Appl Pharm Sci. 2017; 7(5):142-146. DOI: 10.7324/JAPS.2017.70525.
Wongwanakul R, Aueviriyavit S, Furihata T, Gonil P, Sajomsang W, Maniratanachote R, Jianmongkol S. Quaternization of high molecular weight chitosan for increasing intestinal drug absorption using Caco-2 cells as an in vitro intestinal model. Sci Rep. 2023; 13:7904. http://doi.org/10.1038/s41598-023-34888-0.
Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR, Siebenhofer A. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: Systematic review and meta-analysis. Diabetologia 2008; 51:941–951. doi: 10.1007/s12020-016-1039-x.
Heise T, Linnebjerg H, Coutant D, LaBell E, Zijlstra E, Kapitza C, Bue-Valleskey J, Zhang Q, Dellva MA, Leohr J. Ultrarapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes Obes Metab. 2020; 22(10):1789-1798. doi: 10.1111/dom.14094.
Matthew J, Sankar P, Varacallo M. Physiology, Blood Plasma. StatPearls Publishing LLC. 2023.
Glenn A and Armstrong CE. Physiology of red and white blood cells. Anaesth Intensive Care Med. 2019; 20(3):170-174. https://doi.org/10.1016/j.mpaic.2019.01.001.
Holinstat M. Normal platelet function. Cancer Metastasis Rev. 2017; 36(2):195-198. doi:10.1007/s10555-017-9677-x.
Guo X, Sun T, Zhong R, Ma L, You C, Tian M, Li H, Wang C. Effect of chitosan oligosaccharides on human blood components. Front Pharmacol. 2018; 9:1412. doi:10.3389/fphar.2018.01412.
Olorunsola EO, Davies KG, Ibiang KP, Esukpa PC, Uwaechi EG, Ahsan F. Prosochit®-based nanoparticulate system of insulin for oral delivery: design, formulation and characterization. J Appl Pharm Sci. 2023; 13(03):044–052. DOI: 10.7324/JAPS.2023.90862.
De Vos A, Heimberg H, Quartier E, Huypens P, Bouwens L, Pipeleers D, Schuit F. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. J Clin Investig. 1995; 96:2495. doi: 10.1172/JCI118308.
Mohammed NO, Akolade JO, Usman LA, Oloyede OB. Haematological parameters of alloxan-induced diabetic rats treated with leaf essential oil Hoslundia opposita (Vahl). EXCLI J. 2012; 11:670-676. PMCID: PMC4874321.
Zhang H, Yang Z, Zhang W, Niu Y, Li X, Qin L, Su Q. White blood cell serotypes and risk of type 2 diabetes. J Diabetes Complications 2017; 31(3):31-37. https://doi.org/10.1016/j.jdiacomp.2016.10.029.
Sindelar DK, Chu CA, Venson P, Donahue EP, Neal DW, Cherrington AD. Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes 1998; 47:523–529. doi: 10.2337/diabetes.47.4.523.
Bergman RN. Non-esterified fatty acids and the liver: Why is insulin secreted into the portal vein? Diabetologia 2000; 43:946–952. doi: 10.1007/s001250051474.